Servier will be responsible for development and global commercialisation of the therapy for several indications.

Wedbush reissued their outperform rating on shares of Black Diamond Therapeutics (NASDAQ:BDTX – Free Report) in a research ...

Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support ...

Shares of Black Diamond Therapeutics, Inc. (BDTX) jumped around 21% as of Wednesday noon after the company announced it had ...

The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncology Servier will ...

Stock analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for Black Diamond Therapeutics in a ...

Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...

Black Diamond said Servier will develop and commercialize BDTX-4933, a small molecule designed by the Cambridge, Mass., company to address unmet medical needs in RAF/RAS-mutant solid tumors.

Black Diamond Therapeutics presents a compelling investment opportunity with strong potential, balanced by inherent biotech ...

Servier and Black Diamond Therapeutics (BDTX) announced a strategic worldwide licensing agreement for BDTX-4933, a potential best-in-class ...

March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage ...